‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search

8-K filing — Bausch & Lomb Corp (BLCO)

Filed: 2026-10-13 AccNo: 0000950103-26-015460 Size: 372 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Why Is Bausch + Lomb Stock Falling Monday?

Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.

Bausch + Lomb shares are trading lower. The company announced the appointment of Chairman Thomas Appio as interim CEO following Brent Saunders' departure, while also indicating it expects to raise full-year 2026 adjusted EBITDA guidance.

Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D

Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The

Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?

Cooper Companies director Paul Keel purchased 4,701 shares worth $250,000 at $53.18 per share on September 11, 2026, following a 21% year-long stock decline. The insider buy is viewed as a bullish signal, suggesting confidence in the company's long-term growth prospects. Keel, who recently joined Cooper's board in May, brings extensive experience from his CEO role at Envista Holdings and prior positions at 3M.

Barclays Initiates Coverage On Cooper Companies with Equal-Weight Rating, Announces Price Target of $60